Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Export streamlining covers significant, nonsignificant risk devices with IDEs -- FDA proposal.

This article was originally published in The Gray Sheet

Executive Summary

EXPORT OF INVESTIGATIONAL DEVICES WITHOUT FDA REVIEW will be allowed for both significant risk devices that have an approved investigational device exemption and nonsignificant risk products that do not require IDEs, the agency says in a proposed rule expected to be published in the Federal Register the week of Nov. 6. The proposal would allow devices that have approved IDEs to be exported to countries that say they will accept the products without FDA review.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel